Summit Therapeutics Inc. (SMMT) Stock Analysis — Fair Value, Risk & Moat Rating
NGM · Healthcare · Biotechnology
Is Summit Therapeutics Inc. a safe investment right now?
Summit Therapeutics Inc.'s Altman Z-Score of 115.99 places it in the safe zone. Fair value estimate is not available for this stock. Moat rating: 2.6/5 stars.
Could Summit Therapeutics Inc. go bankrupt? Altman Z-Score analysis
Z-Score of 115.99 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives SMMT's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.8617 | 1.2 | 1.03 |
| B · Retained Earnings / Total Assets | RE / TA | -3.0541 | 1.4 | -4.28 |
| C · EBIT / Total Assets | EBIT / TA | -1.4371 | 3.3 | -4.74 |
| D · Market Cap / Total Liabilities | MCap / TL | 206.6251 | 0.6 | 123.98 |
| E · Revenue / Total Assets | Rev / TA | 0 | 1.0 | 0.0 |
How has SMMT's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 21.24 | Safe |
| 2023 | 75.8 | Safe |
| 2024 | 240.04 | Safe |
| 2025 | 115.99 | Safe |
Source: Calculated from SMMT's latest 10-K filing on SEC EDGAR.
What is Summit Therapeutics Inc. actually worth?
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Summit Therapeutics Inc. have a durable competitive advantage?
Moat rating: 2.6/5.
What makes up SMMT's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 2/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 3/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is SMMT's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | -11.6% | — |
| 2023 | -336.8% | Declining |
| 2024 | -54.7% | Rising |
| 2025 | -163.8% | Declining |
Source: ROIC calculated from SEC EDGAR filings.
Is Summit Therapeutics Inc.'s dividend safe?
Summit Therapeutics Inc.'s key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | Declining |
| Net Income | −$1.1B | −$0.2B | −$0.1B | Declining |
| Free Cash Flow | −$0.3B | −$0.1B | −$0.0B | Declining |
Recent events that affect our SMMT analysis
SMMT earnings report scheduled
Upcoming report. Consensus EPS estimate: $-0.21. Revenue estimate: $40850.00.
SMMT analyst consensus: 71% bullish (12 of 17 analysts)
1 Strong Buy, 11 Buy, 4 Hold, 0 Sell, 1 Strong Sell. Consensus target: $31.06 (26.4% upside).
SMMT missed EPS estimates by 106.7%
Reported EPS: $-0.21 vs estimate $-0.10.
SMMT filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT missed EPS estimates by 429.3%
Reported EPS: $-0.23 vs estimate $-0.04.
SMMT filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT missed EPS estimates by 721.4%
Reported EPS: $-0.57 vs estimate $-0.07.
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT beat EPS estimates by 3.0%
Reported EPS: $-0.07 vs estimate $-0.07.
SMMT filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT missed EPS estimates by 3.3%
Reported EPS: $-0.06 vs estimate $-0.06.
SMMT filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
SMMT filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about Summit Therapeutics Inc.
What is Summit Therapeutics Inc. stock price today?
Summit Therapeutics Inc. (SMMT) stock price is $24.58 as of the latest market close, traded on the NASDAQ exchange.
What does Summit Therapeutics Inc. do?
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). It has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC.
What is Summit Therapeutics Inc. market cap?
Summit Therapeutics Inc. has a market capitalization of $19.08B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is SMMT in?
Summit Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. It trades on the NASDAQ under the ticker symbol SMMT.
Is SMMT stock overvalued or undervalued?
We do not have sufficient earnings data to produce a reliable fair value estimate for Summit Therapeutics Inc. at this time. Stocks without stable earnings history are difficult to value using traditional models.
What is SMMT stock forecast and analyst target price?
Based on 14 Wall Street analysts, the consensus price target for Summit Therapeutics Inc. is $31.06, implying upside of 26.4% from the current price.
- Analyst High Target: $45.82
- Analyst Low Target: $11.99
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Summit Therapeutics Inc. revenue and earnings growing?
Here are the analyst consensus growth estimates for Summit Therapeutics Inc.:
- Revenue growth (current year est.): 0.0%
- EPS growth (current year est.): 17.9%
- Revenue growth (next year est.): 1033.7%
- EPS growth (next year est.): 0.4%
What are Summit Therapeutics Inc.'s key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $0.0B | Declining |
| Net Income | −$1.1B | Declining |
| Free Cash Flow | −$0.3B | Declining |
What is SMMT's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Forward P/E (next 12 months est.): -20.9x
How volatile is SMMT stock?
Summit Therapeutics Inc. has a beta of -1.37, meaning it is less volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Summit Therapeutics Inc. have?
Summit Therapeutics Inc.'s balance sheet shows:
- Total Cash: $713.4M
- Total Debt: $20.9M
- Net Cash Position: $692.6M
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is Summit Therapeutics Inc.'s free cash flow?
Summit Therapeutics Inc. generated $84.1M in trailing twelve-month free cash flow (from $-322.9M in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does Summit Therapeutics Inc. pay a dividend?
Summit Therapeutics Inc. does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.
Is Summit Therapeutics Inc. at risk of going bankrupt?
Summit Therapeutics Inc.'s Altman Z-Score is 115.99, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Summit Therapeutics Inc. have a durable competitive advantage?
Summit Therapeutics Inc. scores 2.6/5 stars (Narrow moat · eroding) in our moat analysis:
- ROIC Stability: 2/5
- Gross Margin Trend: 3/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is SMMT's return on equity (ROE)?
Summit Therapeutics Inc.'s return on equity is -206.1%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy SMMT stock?
SMMT shares can be purchased through any brokerage account that provides access to the NASDAQ. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol SMMT
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is SMMT a value stock or speculative?
FairValueLabs classifies Summit Therapeutics Inc. as Pure Speculation. It lacks the financial stability or valuation margin typically required for value investing. This stock is considered high risk.
Who is the CEO of Summit Therapeutics Inc.?
The current CEO of Summit Therapeutics Inc. is Dr. Mahkam Zanganeh D.D.S., M.B.A..
What is SMMT's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $-1.44
- Forward EPS (next 12 months est.): $-1.18
- Analyst consensus EPS (this year): $-0.88
- Analyst consensus EPS (next year): $-0.87
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
SMMT analysis methodology: How we calculate fair value, Z-Scores, and moat ratings